(RTTNews) - Hoffmann-La Roche announced that on June 27, 2024, Health Canada granted approval of Alecensaro monotherapy as adjuvant treatment following tumour resection for patients with stage IB to IIIA anaplastic lymphoma kinase-positive non-small cell lung cancer. The company noted that Alecensaro is the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumour.
The company said Alecensaro reduced the risk of disease recurrence or death by 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
